Innate Pharma Rallies In Morning Trade

Innate Pharma S.A. (IPHA) shares are rising more than 29 percent on Thursday morning trade. The company said AstraZeneca will make two oral presentations on COAST phase 2 trial of Innate's monalizumab in combination with durvalumab. Further, Innate will present pre-clinical data from multi specific NK cell engager platform ANKET.

The presentation at ESMO 2021 Virtual Congress on Monalizumab will be on September 17 and the ANKET presentation will be on September 18.

Currently, shares are at $4.58, up 29.17 percent from the previous close of $3.55.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Follow RTT